Document is current

Article History

Received: 10 October 2022

Accepted: 5 December 2022

First Online: 12 January 2023

Declarations

:

: Before including the first patient, the trial protocols of both trials had been registered (clinicaltrials.gov Identifier: NCT00670254 [], NCT00832039 []) and approved by the leading ethics board of Jena University Hospital and the institutional review boards of all participating institutions []. Both trials were carried out according to the Declaration of Helsinki (October 2013) and in both trials, written informed consent, including secondary analyses, was obtained from all study participants [].

: All authors critically reviewed and approved the final submitted version of the manuscript. All authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

: T. Schmoch reports that he has received lecture fees from Mitsubishi Tanabe Pharma GmbH, CSL Behring GmbH (Germany). T. Brenner reports that he has received honoraria for lectures or advisory boards: Baxter Deutschland GmbH, Schöchl medical education GmbH (Germany), Boehringer Ingelheim Pharma GmbH (Germany), CSL Behring GmbH (Germany), Astellas Pharma GmbH (Germany), B. Braun Melsungen AG (Germany), Lücke Kongresse GmbH (Germany), Sedana medical Germany GmbH (Germany), Shionogi GmbH (Germany) and MSD Sharp & Dohme GmbH (Germany) and advisory board and consulting activity for Baxter Deutschland GmbH (Germany). Furthermore, he received research funding from Deutsche Forschungsgemeinschaft (DFG), Dietmar Hopp Stiftung, Innovationsfonds of the Gemeinsamer Bundesausschuss (G-BA), and Stiftung Universitätsmedizin Essen. Patrick Möhnle reports that he has received reimbursement of conference fees and travel and accommodation expenses, and lecture fees from Bayer (Germany), Biotest (Germany), CSL Behring (Germany), NovoNordisk (Germany), Pfizer (Germany), Roche (Germany), Shire/Takeda, and SOBI (Germany) and advisory board member at CSL Behring (Germany). M.A. Weigand reports that he has received lecture fees from GE Healthcare (Germany), Gilead (Germany), Köhler Chemie (Germany), MSD Sharp & Dohme (Germany), Pfizer Pharma (Germany), and Boehringer Ingelheim (Germany) and was member of advisory boards at B. Braun (Germany), Gilead (Germany), MSD Sharp & Dohme (Germany), and Shionogi (Germany). P. Meybohm and/or the Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg (Wuerzburg, Germany) received research grants from the German Research Foundation (ME 3559/1-1, ME 3559/3-1), BMBF (01KG1815), BMG (ZMVI1-2520DAT10E); grants from B. Braun Melsungen, CSL Behring, Fresenius Kabi, and Vifor Pharma for the implementation of Frankfurt’s Patient Blood Management Program; honoraria for scientific lectures from Biotest AG, Vifor Pharma, CSL Behring, and Pharmacosmos. Michael Bauer, Frank Bloos, Holger Bogatsch, Josef Briegel, Gunnar Elke, Didier Keh and Markus Löffler declare that they have no competing interest.